- Creso Pharma (CPH) progresses activities for its phase two clinical trials, to test the effectiveness of psilocybin in treating post-traumatic stress disorder (PTSD)
- The company applied to include additional cohorts in the study, which will allow it to receive data on how psilocybin interacts with common medication used by PTSD sufferers
- CPH expects to receive an amended Clinical Trial Authorisation shortly before it begins administering the first dosages, subject to ethics approval
- In addition it appointed KGK Science and Dr Gosia Eve Phillips to ensure a smooth study
- Shares are trading 13.6 per cent higher today at 5 cents each at 12:43 pm AEST
Creso Pharma (CPH) has progressed activities for its phase two clinical trials, to test the effectiveness of psilocybin in treating post-traumatic stress disorder (PTSD).
The company applied to broaden its study to include cohorts currently using Selective Serotonin Reuptake Inhibitors (SSRIs), with potential patients not required to stop using prescribed medication until a week before the trial’s commencement.
By expanding the trial, it will receive additional data on how psilocybin interacts with common medication used by PTSD sufferers.
CPH expects to receive an amended Clinical Trial Authorisation shortly before it begins administering the first dosages, subject to ethics approval.
The final submissions for ethics approval have been lodged, with an outcome due soon.
In addition, the company made a number of new appointments to ensure a smooth trial.
This includes KGK Science, which will replace True North Clinical Research to assist with clinical trial initiatives.
KGK was appointed due to its expertise and cost-effectiveness, with compensation of CAD$339,440 (A$383,209) payable.
Meanwhile, Dr Gosia Eve Phillips was assigned to the role of Principal Investigator.
Shares were trading 13.6 per cent higher today at 5 cents each at 12:43 pm AEST.